Bristol-Myers Squibb’s Baraclude has $314 million in US annual sales.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal Circuit today upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s entecavir compound claim of U.S. Patent No. 5, 206, 244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA).
Teva will finalize the launch plans for this product once it receives final approval from the FDA.
Baraclude is marketed in the U.S. by Bristol-Myers Squibb and had annual sales of approximately $314 million in the United States, according to IMS data as of March 2014.